Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

Biederman, Joseph; Mick, Eric O.; Surman, Craig; Doyle, Robert; Hammerness, Paul; Michel, Evan; Martin, Jessica; Spencer, Thomas J
January 2007
BMC Psychiatry;2007, Vol. 7, p49
Academic Journal
Background: The main aim of this study was to compare the safety and efficacy of IR MPH administered three times daily to those of once daily OROS-MPH. Methods: Subjects were outpatient adults satisfying full diagnostic criteria for DSM-IV ADHD between 19 and 60 years of age. Data from two independently conducted 6-week placebo controlled, randomized clinical trials of IR-MPH (tid) and of OROS-MPH were pooled to create three study groups: Placebo (N = 116), IR-MPH (tid) (N = 102) and OROS-MPH (N = 67). Results: Eight-five percent (N = 99) of placebo treated subjects, 77% (N = 79) of the IR-MPH (tid) treated subjects, and 82% (N = 55) of the OROS-MPH treated subjects completed the 6-week trial. Total daily doses at endpoint were 80.9 ± 31.9 mg, 74.8 ± 26.2 mg, and 95.4 ± 26.3 mg in the OROS-MPH, IR-MPH (tid), and placebo groups, respectively. At endpoint, 66% (N = 44) of subjects receiving OROS-MPH and 70% (N = 71) of subjects receiving IR-MPH (tid) were considered responders compared with 31% (N = 36) on placebo. Conclusion: Comparison of data from two similarly designed, large, randomized, placebocontrolled, trials, showed that equipotent daily doses of once daily OROS-MPH had similar efficacy to that of TID administered IR MPH. Trial Registration: The trial of OROS-MPH was registered at clinicaltrials.gov, number NCT00181571.


Related Articles

  • The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Bouffard, Rachelle; Hechtman, Lily; Minde, Klaus; Iaboni-Kassab, Fiorella // Canadian Journal of Psychiatry;Sep2003, Vol. 48 Issue 8, p546 

    Objective: To evaluate the efficacy of methylphenidate in treating adults with attention-deficit hyperactivity disorder (ADHD), using subjective (self-report) and objective (computerized test) measures.Method: This double-blind crossover trial of placebo vs...

  • Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Mattingly, Greg W.; Weisler, Richard H.; Young, Joel; Adeyi, Ben; Dirks, Bryan; Babcock, Thomas; Lasser, Robert; Scheckner, Brian; Goodman, David W. // BMC Psychiatry;2013, Vol. 13 Issue 1, p1 

    Background: Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/ hyperactivity disorder (ADHD). This study examined clinical response and...

  • Open-Label Dose Optimization of Methylphenidate Modified Release Long Acting (MPH-LA): A Post Hoc Analysis of Real-Life Titration from a 40-Week Randomized Trial. Huss, Michael; Ginsberg, Ylva; Arngrim, Torben; Philipsen, Alexandra; Carter, Katherine; Chen, Chien-Wei; Gandhi, Preetam; Kumar, Vinod // Clinical Drug Investigation;Sep2014, Vol. 34 Issue 9, p639 

    Background and Objectives: In the management of attention-deficit hyperactivity disorder (ADHD) in adults it is important to recognize that individual patients respond to a wide range of methylphenidate doses. Studies with methylphenidate modified release long acting (MPH-LA) in children have...

  • Methylphenidate.  // Reactions Weekly;9/18/2010, Issue 1319, p32 

    The article describes the cases of three patients who presented with psychotic symptoms while receiving treatment with methylphenidate for attention-deficit/hyperactivity disorder (ADHD), referencing a study published in the August 2010 issue of the journal "Clinical Neuropharmacology."

  • A 55-year-old man with attention-deficit/hyperactivity disorder. Biederman, Joseph; Biederman, J // JAMA: Journal of the American Medical Association;9/23/98-9/30/98, Vol. 280 Issue 12, p1086 

    Examines the case of a 55-year-old man diagnosed with attention-deficit/hyperactivity disorder (ADHD). His occupation; Memory of difficulties; Diagnosis of ADHD; Unremarkable medical and family history; Effectiveness of treatment with methylphenidate hydrochloride (Ritalin); His understanding...

  • Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD). Retz, Wolfgang; Retz-Junginger, Petra // European Archives of Psychiatry & Clinical Neuroscience;Nov2014 Supplement, Vol. 264, p35 

    Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent mental disorder of childhood, which often persists in adulthood. Methylphenidate (MPH) is one of the most effective medications to treat ADHD, but also few adult patients show no sufficient response to this drug. In this...

  • Methylphenidate.  // Reactions Weekly;3/22/2008, Issue 1194/1195, p24 

    The article describes the case of a 22-year-old woman with attention deficit hyperactivity disorder who developed pseudolymphoma during treatment with methylphenidate. The patient experienced recurrent, mildly pruritic crops of painless lesions that were mostly localised to her proximal upper...

  • Attention Deficit Disorder in Adults: Clinical and Psychophysiological Features and Treatment. Chutko, L.; Surushkina, S.; Yakovenko, E.; Nikishena, I.; Anisimova, T. // Neuroscience & Behavioral Physiology;Nov2014, Vol. 44 Issue 9, p1078 

    We present here the results of studies of 34 patients aged 18-30 years with attention deficit hyperactivity disorder (ADHD) (ICD-10 F90.0). The form of ADHD with predominance of inattention was more frequent in adults (50% of patients), while the form with predominance of hyperactivity (11.7%)...

  • Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Krause, Johanna; La Fougere, Christian; Krause, Klaus-Henning; Ackenheil, Manfred; Dresel, Stefan H. // European Archives of Psychiatry & Clinical Neuroscience;2005, Vol. 255 Issue 6, p428 

    In this study, we investigated whether availability of striatal dopamine transporter (DAT) may have an influence on the response of adult patients with attention deficit hyperactivity disorder (ADHD) on methylphenidate (MPH). In 18 non–smoking and non–medicated adult patients with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics